SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from HEMCURE INC (CIK 0000810208) — Oct 14, 2005

HEMCURE INC (CIK 0000810208)
Date: Oct. 14, 2005 · CIK: 0000810208 · Accession: 0001269678-05-000195

AI Filing Summary & Sentiment

Referenced dates: October 3, 2005

Date
October 13, 2005
Author
Michael Friess
Form
CORRESP
Company
HEMCURE INC (CIK 0000810208)

Letter

October 13, 2005 Securities and Exchange Commission Washington, D.C. 20549

Re: Hemcure, Inc. Registration Statement on Form 10-SB File No. 0-51543

Dear Sirs:

In response to the staff's comment letter dated October 3, 2005 regarding Hemcure, Inc.'s Form 10-SB filing we acknowledge that:

o The Company is responsible for the adequacy and accuracy of the disclosure in the filings;

o The SEC staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

o The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Sincerely,
Michael Friess
Chief Executive Officer
Hemcure, Inc.

Show Raw Text
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>

October 13, 2005

Securities and Exchange Commission
Washington, D.C. 20549

         Re:   Hemcure, Inc.
               Registration Statement on Form 10-SB
               File No. 0-51543

Dear Sirs:

In response to the staff's comment letter dated October 3, 2005 regarding
Hemcure, Inc.'s Form 10-SB filing we acknowledge that:

     o    The Company is responsible for the adequacy and accuracy of the
          disclosure in the filings;

     o    The SEC staff comments or changes to disclosure in response to staff
          comments do not foreclose the Commission from taking any action with
          respect to the filing; and

     o    The Company may not assert staff comments as a defense in any
          proceeding initiated by the Commission or any person under the federal
          securities laws of the United States.

Sincerely,

Michael Friess
Chief Executive Officer
Hemcure, Inc.

</TEXT>
</DOCUMENT>